Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 4776 - 4800 of 5845 in total
Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
Investigational
Matched Description: … Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, …
Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
Investigational
Matched Description: … Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small …
Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
Investigational
Matched Description: … Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), …
Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.
Investigational
Matched Description: … Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma …
Licogliflozin is under investigation in clinical trial NCT03320941 (A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity).
Investigational
Matched Description: … investigation in clinical trial NCT03320941 (A Dose-finding Study to Evaluate the Change in Weight After Treatment
TZP-102 is under investigation in clinical trial NCT01452815 (Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis).
Investigational
Matched Description: … investigation in clinical trial NCT01452815 (Affects of Once-daily Oral Administration of TZP-102 on the Treatment
Paltusotine is under investigation in clinical trial NCT04261712 (A Study to Evaluate the Long-term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)).
Investigational
Matched Description: … clinical trial NCT04261712 (A Study to Evaluate the Long-term Safety and Efficacy of Paltusotine for the Treatment
ALT-P1 is a long-acting recombinant human growth hormone fused to an alpha1-antitrypsin variant. It is under investigation for the treatment of growth hormone deficiency.
Investigational
Matched Description: … It is under investigation for the treatment of growth hormone deficiency. …
Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90). It is developed for the treatment of several types of cancer, solid tumors or chronic myelogenous leukemia.
Investigational
Matched Description: … It is developed for the treatment of several types of cancer, solid tumors or chronic myelogenous leukemia …
Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential antipsychotic drug for the treatment of schizophrenia.
Investigational
Matched Description: … different functions, primarily for irritable bowel syndrome and as a potential antipsychotic drug for the treatment
Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell Cancer and Head and Neck Cancer.
Investigational
Matched Description: … Zalutumumab has been investigated for the treatment of Squamous Cell Cancer and Head and Neck Cancer. …
BMS-214662 has been used in trials studying the treatment of Childhood Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia, and Adult Acute Promyelocytic Leukemia (M3), among others.
Investigational
Matched Description: … BMS-214662 has been used in trials studying the treatment of Childhood Myelodysplastic Syndromes, Refractory …
ABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.
Investigational
Matched Description: … ABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck …
Phenserine is under development by Axonyx, a US biopharmaceutical company that focuses on treatments for dementia. Phenserine is a next generation acetylcholinesterase (AChE) inhibitor indicated for the treatment of AD. Unlike currently marketed AChE inhibitors, it has a dual mechanism of action that also includes anti-amyloid activity, which may confer...
Investigational
Matched Description: … Phenserine is a next generation acetylcholinesterase (AChE) inhibitor indicated for the treatment of ... substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment
Fasinumab is a human IgG1k monoclonal antibody targeted against nerve growth factor (NGF). It is currently under investigation for the treatment osteoarthritic pain and has demonstrated significantly greater pain relief and functional improvement as compared to standard therapy (i.e. NSAIDs and/or opioids) in this patient population. NGF was first discovered...
Investigational
Matched Description: … It is currently under investigation for the treatment osteoarthritic pain[A241045] and has demonstrated ... for its role in nociceptive signaling transduction and has thus become an attractive target in the treatment
Loxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain . The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique characteristic compared to others in the opioid class...
Investigational
Matched Description: … Nektar Therapeutics has filed an application for FDA approval of Loxicodegol for use in the treatment ... Loxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment
TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available darunavir. It is being investigated for use in HIV-1 infections. TMC-310911 has shown marked activity against a variety of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to...
Investigational
Matched Description: … currently being investigated, in combination with other HIV therapies and antivirals, as a potential treatment ... , and may be less likely to generate resistance, making it a potentially desirable therapy for both treatment-naive …
NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile. The product is intended for basal insulin treatment of diabetes mellitus.
Investigational
Matched Description: … The product is intended for basal insulin treatment of diabetes mellitus. …
RAV12 is investigated for use/treatment in solid tumors. RAV12 is a solid. RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.
Investigational
Matched Description: … RAV12 is investigated for use/treatment in solid tumors. RAV12 is a solid. …
KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07. It is being developed by Kalypsys.
Investigational
Matched Description: … KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of …
Bradanicline, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7(α7). Bradanicline belongs to a new class of drugs for the treatment of central nervous system diseases and disorders.
Investigational
Matched Description: … Bradanicline belongs to a new class of drugs for the treatment of central nervous system diseases and …
Azintuxizumab vedotin is under investigation in clinical trial NCT02951117 (A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment).
Investigational
Matched Description: … in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment
SBT-100 is an anti-signal transducer and activator of transcription 3 (STAT3) B VHH13 single-domain antibody (sdAb). It was granted orphan drug designation by the FDA for the treatment of pancreatic cancer and osteosarcoma.[L44131,L44136]
Investigational
Matched Description: … It was granted orphan drug designation by the FDA for the treatment of pancreatic cancer and osteosarcoma …
BMN-351 is a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA. It is under investigation for the treatment of Duchenne Muscular Dystrophy (DMD).
Investigational
Matched Description: … It is under investigation for the treatment of Duchenne Muscular Dystrophy (DMD). …
Pictilisib has been used in trials studying the treatment of Solid Cancers, Breast Cancer, Advanced Solid Tumours, Metastatic Breast Cancer, and Non-Hodgkin's Lymphoma, Solid Cancers, among others.
Investigational
Matched Description: … Pictilisib has been used in trials studying the treatment of Solid Cancers, Breast Cancer, Advanced Solid …
Displaying drugs 4776 - 4800 of 5845 in total